[Lithium valproate: its neuropharmacological spectrum and effect on transmitter amino acid content of the brain of rats].
The authors studied lithium valproate synthesized at the Institute of Pharmacology, Academy of Medical Sciences of the USSR, and compared it with sodium valproate (depakin, France). It was discovered that like sodium valproate, lithium valproate has a marked anticonvulsant activity, being also effective in experimental seizures induced by bicucullin, exerts a moderate sedative action (potentiation of sodium thiopental and hexenal anesthesia), and a distinct tranquilizing effect in experimental outward inhibition of the conditioned active avoidance response. At the same time the presence in the molecule of lithium ions led to a change in the neurochemical profile of valproate, manifested by an increase in the rat brain content of GABA and glutamate.
D000596:Amino Acids / Q000378:metabolism*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003214:Conditioning, Classical / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D008094:Lithium / Q000494:pharmacology*; D016651:Lithium Carbonate; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism*; D051381:Rats; D014635:Valproic Acid / Q000494:pharmacology*
D000596:Amino Acids; D000927:Anticonvulsants; D018377:Neurotransmitter Agents; D016651:Lithium Carbonate; D014635:Valproic Acid; D008094:Lithium
Litiia val'proat: neĭrofarmakologicheskiĭ spektr i vliianie na soderzhanie mediatornykh aminokilsot v mozge krys.